Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Gains 9%; BSE HEALTHCARE Index Up 0.6%
Tue, 27 Aug 11:35

Panacea Biotech Gains 9%; BSE HEALTHCARE Index Up 0.6%Image source: DNY59/www.istockphoto.com

Panacea Biotech share price has zoomed 9% and is presently trading at Rs 259.1.

Meanwhile, the BSE HEALTHCARE index is at 42,400.8 (up 0.6%).

Among the top gainers in the BSE HEALTHCARE index today are Jubilant Pharmova (up 3.7%) and HIKAL CHEMIC (up 2.1%).

ASTRAZENECA PHARMA (down 1.2%) and POLY MEDICURE (down 1.1%) are among the top losers today.

Over the last one year, Panacea Biotech has moved up from Rs 139.2 to Rs 259.1, registering a gain of Rs 119.9 (up 86.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,099.5 to 42,400.8, registering a gain of 50.9% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 131.1%), Glenmark Pharma (up 125.5%) and SUVEN PHARMACEUTICALS (up 105.8%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,889.5 (up 0.2%).

The top gainers among the BSE Sensex today are L&T (up 2.3%) and Maruti Suzuki (up 1.6%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.

In the meantime, NSE Nifty is at 25,068.9 (up 0.2%). L&T and Maruti Suzuki are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,433.3 to 81,889.5, registering a gain of 16,456.2 points (up 25.1%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -55.9.


Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 9%; BSE HEALTHCARE Index Up 0.6%". Click here!